OVERVIEW

LL-37 5 mg (CAP-18) is a synthetic form of LL-37, a human antimicrobial peptide derived from the precursor protein CAP-18 (cathelicidin antimicrobial peptide). LL-37 plays an important role in the innate immune system, serving as one of the body’s first lines of defense against bacterial, viral, and fungal pathogens. It is naturally produced by immune cells and epithelial tissues, where it contributes to microbial membrane disruption and immune signaling. Beyond its antimicrobial activity, LL-37 has been studied for its involvement in wound healing, inflammation regulation, and tissue repair. The 5 mg designation typically refers to a lyophilized research-grade quantity intended for controlled laboratory investigation.

In research settings, LL-37 has drawn attention for its broad-spectrum antimicrobial properties and its ability to modulate immune responses. It appears to influence cytokine production, chemotaxis, and angiogenesis, suggesting potential applications in studies related to skin health, chronic wounds, and immune system balance. However, because LL-37 can also stimulate inflammatory pathways under certain conditions, careful dosing and monitoring are emphasized in experimental models. While promising findings continue to emerge, LL-37 remains primarily a research peptide rather than a widely approved therapeutic agent. Ongoing studies aim to better define its safety profile, optimal applications, and long-term biological effects.